PL4522143T3 - Leczenie bólu związanego z sensytyzacją ośrodkową - Google Patents

Leczenie bólu związanego z sensytyzacją ośrodkową

Info

Publication number
PL4522143T3
PL4522143T3 PL23837005.0T PL23837005T PL4522143T3 PL 4522143 T3 PL4522143 T3 PL 4522143T3 PL 23837005 T PL23837005 T PL 23837005T PL 4522143 T3 PL4522143 T3 PL 4522143T3
Authority
PL
Poland
Prior art keywords
pain associated
treating pain
central sensitization
sensitization
central
Prior art date
Application number
PL23837005.0T
Other languages
English (en)
Inventor
Basil Rigas
Original Assignee
Medicon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicon Pharmaceuticals, Inc. filed Critical Medicon Pharmaceuticals, Inc.
Publication of PL4522143T3 publication Critical patent/PL4522143T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL23837005.0T 2022-11-23 2023-11-21 Leczenie bólu związanego z sensytyzacją ośrodkową PL4522143T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202263384795P 2022-11-23 2022-11-23
US202263384793P 2022-11-23 2022-11-23
US202263384796P 2022-11-23 2022-11-23
US202263384794P 2022-11-23 2022-11-23
US202263384792P 2022-11-23 2022-11-23
US202263384790P 2022-11-23 2022-11-23
US202363483353P 2023-02-06 2023-02-06
PCT/US2023/080646 WO2024112725A1 (en) 2022-11-23 2023-11-21 Treating pain associated with central sensitization

Publications (1)

Publication Number Publication Date
PL4522143T3 true PL4522143T3 (pl) 2025-10-13

Family

ID=89378489

Family Applications (1)

Application Number Title Priority Date Filing Date
PL23837005.0T PL4522143T3 (pl) 2022-11-23 2023-11-21 Leczenie bólu związanego z sensytyzacją ośrodkową

Country Status (16)

Country Link
US (1) US20250345350A1 (pl)
EP (3) EP4622638A1 (pl)
JP (2) JP2025541616A (pl)
KR (2) KR20250121336A (pl)
CN (2) CN120603589A (pl)
AU (2) AU2023385702A1 (pl)
ES (1) ES3036667T3 (pl)
HR (1) HRP20251034T1 (pl)
HU (1) HUE072771T2 (pl)
MA (1) MA70825B1 (pl)
MD (1) MD4522143T2 (pl)
MX (2) MX2025005910A (pl)
PL (1) PL4522143T3 (pl)
RS (1) RS67089B1 (pl)
SM (1) SMT202500296T1 (pl)
WO (2) WO2024112727A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025111079A1 (en) 2023-11-21 2025-05-30 Medicon Pharmaceuticals, Inc. Isomers of phosphosulindac

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
ITMI20051107A1 (it) * 2005-06-14 2005-09-13 Ctg Pharma S R L Metodo per il trattamento del cancro
WO2009023631A1 (en) 2007-08-10 2009-02-19 Basil Rigas Anti-inflammatory compounds and uses thereof
WO2013130625A1 (en) 2012-02-27 2013-09-06 Basil Rigas Phospho-ester derivatives and uses thereof
CA2885740A1 (en) 2012-09-21 2014-03-27 Basil Rigas Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof
CN107614061A (zh) * 2014-12-01 2018-01-19 阿科莱尔斯疗法公司 用于治疗与疼痛有关的偏头痛和病症方法和组合物
CA3077033A1 (en) 2017-09-28 2019-04-04 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
PL4114403T3 (pl) 2021-05-24 2023-10-09 Medicon Pharmaceuticals, Inc. Leczenie bólu neuropatycznego towarzyszącego neuropatii obwodowej indukowanej przez chemioterapię
RS64402B1 (sr) 2021-05-24 2023-08-31 Medicon Pharmaceuticals Inc Lečenje bola povezanog sa dijabetičkom perifernom neuropatijom

Also Published As

Publication number Publication date
MA70825B1 (fr) 2025-12-31
SMT202500296T1 (it) 2025-09-12
EP4622638A1 (en) 2025-10-01
MX2025005910A (es) 2025-09-02
JP2025541617A (ja) 2025-12-22
EP4522143B1 (en) 2025-07-02
HUE072771T2 (hu) 2025-12-28
KR20250123139A (ko) 2025-08-14
AU2023385700A1 (en) 2025-07-10
EP4603145A3 (en) 2025-11-19
EP4522143C0 (en) 2025-07-02
US20250345350A1 (en) 2025-11-13
KR20250121336A (ko) 2025-08-12
WO2024112725A1 (en) 2024-05-30
RS67089B1 (sr) 2025-09-30
HRP20251034T1 (hr) 2025-10-24
WO2024112727A1 (en) 2024-05-30
MX2025005914A (es) 2025-09-02
CN120603589A (zh) 2025-09-05
CN120569194A (zh) 2025-08-29
JP2025541616A (ja) 2025-12-22
EP4522143A1 (en) 2025-03-19
MD4522143T2 (ro) 2025-11-30
EP4603145A2 (en) 2025-08-20
ES3036667T3 (en) 2025-09-23
AU2023385702A1 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
GB202314527D0 (en) New treatment for pain
GB202309744D0 (en) New treatments for pain
IL315403A (en) Miramatinib treatment
PT4114403T (pt) Tratamento da dor neuropática associada à neuropatia periférica induzida por quimioterapia
HUE072771T2 (hu) A központi szenzitizációval kapcsolatos fájdalom kezelése
GB202016058D0 (en) Therapeautic treatment
CA3274667A1 (en) Treating pain associated with central sensitization
HK40123373A (en) Treating pain associated with central sensitization
GB202405551D0 (en) Combination treatment
GB202006236D0 (en) New treatment
GB202002711D0 (en) Treatment
GB202309922D0 (en) Antisense treatment
IL316821A (en) Cancer treatment with NUC-7738
GB202316077D0 (en) New treatments for pain
GB202304716D0 (en) New treatment
GB202319954D0 (en) Treatment
GB202319658D0 (en) Treatment
GB202318845D0 (en) Treatment
GB202311007D0 (en) Treatment
GB202210430D0 (en) New treatment
GB202218460D0 (en) Treatment
GB202206219D0 (en) New treatment
GB202214206D0 (en) Treatment
GB202204288D0 (en) Treatment
GB202204070D0 (en) Treatment